Care este prețul pentru Gracell Biotechnologies Inc. (GRCL)

Prețul pentru Gracell Biotechnologies Inc. (GRCL) este $10.25

Care este capitalizarea de piață pentru Gracell Biotechnologies Inc. (GRCL)

Capitalizarea de piață pentru Gracell Biotechnologies Inc. (GRCL) este $137.83M

Gracell Biotechnologies Inc. (GRCL) Dividende

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China. The company's leading investigational therapies include: GC012F: A FasTCAR-enhanced autologous CAR-T product designed to target both BCMA and CD19, currently undergoing Phase I clinical trials for multiple myeloma. GC019F: A FasTCAR-enabled CD19-directed autologous CAR-T therapy, which is progressing through Phase I trials for adult B-cell acute lymphoblastic leukemia (B-ALL) and is also in preclinical development for relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL). GC027: A TruUCAR-powered allogeneic CAR-T product targeting CD7, presently in Phase I clinical development for adult T-cell acute lymphoblastic leukemia. Additionally, Gracell's pipeline features: GC007g: A donor-derived allogeneic CAR-T cell therapy directed at CD19, currently in a Phase 1/2 registrational study for r/r B-ALL. GC502: An off-the-shelf, TruUCAR-enabled allogeneic CAR-T candidate engineered to target both CD19 and CD7, which is in Phase I trials for B-cell malignancies. Beyond these, Gracell maintains a broader portfolio of earlier-stage therapeutic candidates addressing diverse oncological conditions, including ovarian cancer, breast cancer, peripheral T cell lymphoma (a subtype of NHL), and T cell lymphoblastic leukemia. Established in 2017, the company's headquarters are situated in Suzhou, China.

An	Dividend (ajustat pentru split de acțiuni)	Schimbă
Nu sunt suficiente date pentru perioada selectată.

Dividend (ajustat pentru split de acțiuni)

Schimbă

Nu sunt suficiente date pentru perioada selectată.

An	Dividend	Schimbă
Nu sunt suficiente date pentru perioada selectată.

Dividend

Schimbă

Nu sunt suficiente date pentru perioada selectată.

Companie	Număr de plăți de dividende	Țara
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Moderna, Inc. MRNA.US	0.00%	US
CSL Limited CSL.AX	64.00%	AU
Lonza Group AG LONN.SW	0.00%	CH

Companie

Număr de plăți de dividende

Țara